IDSA’s recent elections, along with the appointment of current IDSA Treasurer Jeanne Marrazzo, MD, FIDSA (@DrJeanneM) as the next @NIAIDNews director, will bring a new slate of Board members to the Society effective Oct. 16.
Learn more: https://t.co/HHrlWGK8aT
The Critical Care Reviews Book 2022 is now available
https://t.co/R5ABzJVlI8
#CCR22
➡️Best trials of 2021 summarised, critiqued & contextualised
➡️Available as free pdf or physical book
➡️For those in high income countries, we suggest making a small donation to support our work
Impressive new data for real-world effectiveness (VE) of Moderna vaccine in a prospective study of >350,000 vaccinees & matched unvaccinated individuals, w/ virus sequencing
https://t.co/HgnRfeJ3tz
VE hospitalization 96%, symptomatic infection 88%
@BruxvoortKatia@KPSCalResearch
Encouraging new commentary about the very small risk of surface/fomite transmission of #SARSCoV2
https://t.co/bZxqVLwFRz @TheLancetInfDis by Emanuel Goldman @Rutgers_NJMS
Unintended consequences of so much fear surrounding COVID
The Untold Toll — The Pandemic’s Effects on Patients without Covid-19 | NEJM https://t.co/ykSQiLyCkK
THRILLED to announce Philter, our new tool to deidentify clinical text. Now more than ever, safe & responsible sharing of #EHR data is needed to fight pandemics & disease, but text is hardest to share. @BeauNorgeot built a new tool w/ a great team! https://t.co/FVGF49ja3a
first meaningful RCT on hydroxychloroquine
- no effect on viral clearance (despite huge doses)
- no effect on symptomatic improvement
- increased side effects
- for now, use of hydroxychloroquine should probably be limited to RCTs
(blog https://t.co/2nx0LL1mMO)
#COVID19 Here comes another dataset of #Hydroxychloroquine from an open-label randomized controlled trial in China
https://t.co/qW93wMDILK
No difference in 28-day #coronavirus negative conversion rate for HCQ + SOC vs SOC
No difference in 28-day symptoms alleviation rate either
A very good review of what we know of the anti-#COVID19 drug treatments to date
https://t.co/QwMsMyIEQy @JAMA_current by @UTSWNews James Sanders and colleagues
This. The inability to comfort your patients or their families the way they deserve is incredibly challenging. Proud @RWJMS donated iPads to take on this challenge
Teach your family to use video chat services before they need it. #CovidCompassion#NEJM
https://t.co/a8Q6rK4pGJ
A cohort of patients with severe Covid-19 received treatment with remdesivir under a compassionate-use protocol. Improvement in oxygen-support status was observed in 68% of patients, and overall mortality was 13% over a median follow-up of 26 days. #COVID19
fresh study: D-dimer >1,500 strongly correlates with DVT among COVID patients (85% sensi, 89% spec). many limitations, but this supports the concept of empiric anticoagulation if ⬆️⬆️ DDimer & no contraindication.
(fresh blog: https://t.co/sP7Mh82hNF)
#COVID19FOAM
Give the APL abs maybe some efficacy of the plaquenil similar to effect of the APL during lupus flare? Problem with clots that have already formed, would need to start early. Not seeing great efficacy with plaquenil because they are already hypoxemic and Abs had time to form clot
Guide for telephone and video consults for #COVID19 — strongest stimulus for #DigitalHealth and #telehealth in decades:
▪️Most can be managed remotely
▪️Safety-netting is crucial
▪️Data protection regs relaxing
▶️https://t.co/sIJMxTWVhu @bmj_latest by @trishgreenhalgh